Executive Orders Targeting Transgender Rights and Gender Identity Recognition

What Happened

On January 20, 2025 -- his first day back in office -- President Trump signed Executive Order 14168, titled "Defending Women from Gender Ideology Extremism and Restoring Biological Truth to the Federal Government." The order fundamentally redefined how the federal government treats gender identity, with material consequences for transgender, nonbinary, and intersex individuals across federal systems.

Key Provisions

The executive order:

• Defines sex as immutable and binary: The order states that "sex" refers to "an individual's immutable biological classification as either male or female" determined "at conception," and that sex "is not a synonym for and does not include the concept of 'gender identity.'"
• Requires housing by birth sex in detention: Transgender individuals in federal custody, including immigration detention, must be housed according to their sex assigned at birth. Research consistently shows that this placement policy substantially increases the risk of sexual violence against transgender detainees.
• Cuts federal funding for gender-affirming care: The order directs all federal agencies to cease funding for gender-affirming care and prohibits the promotion of "gender ideology."
• Prohibits gender self-identification on documents: Federal agencies are directed to stop allowing individuals to select a gender other than their birth sex on passports, identification, and other federal documents.
• Replaces "gender" with "sex" in federal materials: All federal agencies must replace instances of "gender" with "sex" across regulations, guidance, and communications.

International Law Concerns

The order raises concerns under several international human rights instruments:

Non-discrimination: The ICCPR requires states to guarantee equal protection without discrimination. While the treaty text does not explicitly list gender identity, UN treaty bodies have consistently interpreted the non-discrimination provisions to encompass sexual orientation and gender identity.

Cruel, inhuman, or degrading treatment: Housing transgender women in male detention facilities creates a documented risk of sexual violence and physical assault. The denial of medically necessary gender-affirming care in federal custody may constitute cruel treatment under both the ICCPR (Article 7) and the Convention Against Torture (Article 16). The UN Special Rapporteur on Torture has specifically identified denial of gender-affirming care and discriminatory placement in detention as forms of ill-treatment.

Yogyakarta Principles: While not binding treaty law, the Yogyakarta Principles represent the consensus of international human rights experts on the application of existing international law to gender identity. The executive order contravenes principles on non-discrimination, recognition before the law, and the right to the highest attainable standard of health.

Legal Challenges

Multiple lawsuits have been filed challenging the order. On March 1, 2025, Judge Lauren King blocked the provisions cutting federal funding for programs that "promote gender ideology" and withholding funding from healthcare providers offering gender-affirming care to minors. Other provisions remain in effect.

The National LGBTQ+ Bar Association maintains a litigation tracker documenting the numerous legal challenges proceeding through the courts.

Why This Entry Is Rated Major

This publication treats the order as a major abuse of power because of its concrete, material harms to a vulnerable population:

• Detention violence risk: Housing transgender women with men in federal facilities is not an abstract policy dispute -- it creates quantifiable, documented risk of sexual violence.
• Medical care denial: Withholding medically recognized treatment from people in federal custody, where they have no alternative source of care, raises serious questions about cruel treatment.
• Document erasure: Prohibiting gender self-identification on federal documents affects access to employment, travel, and basic civil participation.
• Scope: The order affects every federal agency, creating cascading effects across immigration, healthcare, military service, education, and civil documentation.

Update: Prison Medical-Care Policy Reaches the Supreme Court (June–September 2026)

The order's directive to withhold gender-affirming care in federal custody produced a second-generation Bureau of Prisons policy in February 2026. That policy would continue mental-health services for inmates diagnosed with gender dysphoria but end hormone therapy, gender-transition surgeries and "social accommodations" such as wigs, chest binders and breast padding. Transgender inmates challenged it in federal court in Washington, D.C.

Senior U.S. District Judge Royce Lamberth blocked the policy in June 2026, describing it as "reverse engineered" to implement the executive order, and ordered the government to continue providing care such as hormone therapy; the Associated Press reported that the bureau does not dispute that gender dysphoria can cause severe effects including depression, anxiety and suicidal thoughts, and that it was providing hormone therapy to more than 600 inmates. On August 26, 2026, Lamberth issued a further order keeping the block in place. In September a divided D.C. Circuit panel declined to pause it.

On September 28, 2026, Solicitor General D. John Sauer asked the Supreme Court to let the policy take effect (Trump v. Kingdom, No. 26A416), arguing that the district court "substitute[d] its own policy judgment" for the bureau's and that prison administrators had determined the policy "is necessary to maintain institutional security." According to the application, the bureau said it revised its policy to align with "the latest scientific information" and that greater access to these interventions would risk turning recipients into "target[s] for attacks" and "breed resentment among other inmates."

The case bears directly on the concern identified above: inmates in federal custody have no alternative source of medical care, so a categorical withdrawal of ongoing hormone therapy is precisely the kind of denial of treatment that UN bodies have identified as potential ill-treatment under Article 7 of the ICCPR and Article 16 of the Convention Against Torture.

Separately, on August 11, 2026, CMS finalized a rule ending federal Medicaid and CHIP payment for gender-affirming care for minors, documented in its own entry.